Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations
July 20, 2017 at 09:30 AM EDT
Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|